In the Hill Country area, home to Camp Mystic and several other summer camps, searchers have found the bodies of 75 people, ...

The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic ...

The acknowledgment that the well-connected Epstein did not have a list of clients to whom underage girls were trafficked ...

Women across the nation have connected online over their unexpected pregnancies, known as "Ozempic babies," while using GLP-1 ...

McALLEN, Texas (AP) — A 27-year-old man was killed Monday after opening fire at a U.S. Border Patrol facility in McAllen, ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Ticker: Wegovy and Zepbound prices fall; ExxonMobil and partner Qatar Energy find new natural gas deposit off Cyprus ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

This month, CVS Caremark announced that it had also signed a deal to make Novo Nordisk’s Wegovy its preferred GLP-1RA starting in July, which concurrently deprioritised coverage for Zepbound.

Key Takeaways The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on ...